Background:

The exact cause of primary dysmenorrhea remains unclear, a gathering of treatment options is accessible to improve symptoms and improve general quality of life. With documented evidence of excessive absenteeism, prolonged use of NSAIDs and poor QoL amid Dysmenorrhea in young females, an easily approachable method to manage the issues is necessary.

Objective:

To assess the effects of diclofenic sodium and mefenamic acid on the severity and systemic symptoms of primary dysmenorrhea in the young age girls of Nursing School in Karachi Pakistan.

Methodology:

This is an observational, prospective study conducted from January 2023 to August 2023, the minimum sample size was 350. Data was collected by pre-structured questionnaire including age, marital status, clinical history, family history. The severity of pain is calculated by the Verbal Multidimensional Scoring System (VMS). Analysis was performed on SPSS-22. Chi-square test was performed keeping <0.05 p value as significant.

Results:
The mean age of participants was 22.15 ±1.9 years. Participants were divided into two groups A & B. Group A prescribed Diclofenic Sodium and Group B prescribed Mefenamic Acid as pain management medicine during the menstrual cycle. The difference in the VMS pain scale after 2 months of intervention was reported as significant, Grade 0 reported 20 (5.7%) and 29 (8.2%) in Group A & B respectively indicating remarkable difference in overall pain severity after using Diclofenic as pain management medicine while slight difference was noted in menfamic acid group.

Conclusion:
The findings contribute to the understanding of pain management options for young women experiencing dysmenorrhea, highlighting the potential advantages of Diclofenic Sodium in improving their quality of life during menstruation.
 

Keywords:

Primary Dysmenorrhea, pain management, diclofenic sodium, menfamic acid